Arterra Bioscience SpA (MIL:ARBS) EBIT: €2.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:ARBS Arterra Bioscience SpA MIL:ARBS
77 GF Score
Price €3.04
GF Value €2.91
Valuation Fairly Valued
View Full Analysis

What is Arterra Bioscience SpA EBIT?

Arterra Bioscience SpA MIL:ARBS -0.33% 77 EBIT is €2.00 Mil as of Dec. 2025. GuruFocus rates MIL:ARBS with a GF Score™ of 77/100 and a GF Value™ of €2.91 (Fairly Valued).

Arterra Bioscience SpA's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €0.91 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €2.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Arterra Bioscience SpA's annualized ROC % for the quarter that ended in Dec. 2025 was 16.94%. Arterra Bioscience SpA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 49.85%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Arterra Bioscience SpA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 10.67%.

Arterra Bioscience SpA  (MIL:ARBS) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Arterra Bioscience SpA's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=1.886 * ( 1 - 0% )/( (9.624 + 12.64)/ 2 )
=1.886/11.132
=16.94 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14.01 - 0.944 - ( 3.442 - max(0, 1.183 - 8.706+3.442))
=9.624

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=14.588 - 0.605 - ( 1.343 - max(0, 0.882 - 6.825+1.343))
=12.64

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Arterra Bioscience SpA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1.826/( ( (1.756 + max(1.834, 0)) + (1.68 + max(2.056, 0)) )/ 2 )
=1.826/( ( 3.59 + 3.736 )/ 2 )
=1.826/3.663
=49.85 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.33 + 1.289 + 0.35) - (0.944 + 0 + 0.191)
=1.834

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.859 + 1.539 + 0.447) - (0.605 + 0 + 0.184)
=2.056

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Arterra Bioscience SpA's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=1.998/18.719
=10.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arterra Bioscience SpA EBIT Related Terms

Arterra Bioscience SpA EBIT Historical Data

* Premium members only.

The historical data trend for Arterra Bioscience SpA's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arterra Bioscience SpA EBIT Chart

Arterra Bioscience SpA Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only 1.28 1.81 1.31 1.70 2.00

Arterra Bioscience SpA Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.05 0.63 1.07 1.09 0.91

MIL:ARBS vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Arterra Bioscience SpA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arterra Bioscience SpA EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arterra Bioscience SpA's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Arterra Bioscience SpA's EV-to-EBIT falls into.


MIL:ARBS
77GF Score
Arterra Bioscience SpA MIL:ARBS
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arterra Bioscience SpA EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €2.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €2.00 Mil mean?
Arterra Bioscience SpA (MIL:ARBS) has a EBIT of €2.00 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Arterra Bioscience SpA.
Is Arterra Bioscience SpA's EBIT too high?
Arterra Bioscience SpA's current EBIT is €2.00 Mil. Overall, Arterra Bioscience SpA has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arterra Bioscience SpA's EBIT compare to VRTX and REGN?
Arterra Bioscience SpA's EBIT of €2.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Arterra Bioscience SpA. Arterra Bioscience SpA's current EBIT is €2.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arterra Bioscience SpA stock overvalued right now?
Based on GuruFocus' analysis, Arterra Bioscience SpA (MIL:ARBS) is currently considered Fairly Valued. The stock's GF Value™ is €2.91, compared to a current price of €3.04 — trading 4.5% above its estimated fair value. The current EBIT is €2.00 Mil. Arterra Bioscience SpA's overall GF Score™ is 77/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Arterra Bioscience SpA (MIL:ARBS), the current EBIT is €2.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arterra Bioscience SpA (MIL:ARBS) Overvalued in 2026?

Based on GuruFocus' analysis, Arterra Bioscience SpA stock appears to be overvalued. The current stock price of €3.04 is trading 4.5% above its estimated GF Value™ of €2.91. GuruFocus considers Arterra Bioscience SpA to be Fairly Valued.

Key valuation signals for MIL:ARBS:

  • EBIT: €2.00 Mil
  • GF Value™: €2.91 vs. price of €3.04 (4.5% above fair value)
  • GF Score™: 77/100

No single metric tells the full story. See the MIL:ARBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arterra Bioscience SpA Business Description

Address via Benedetto Brin, 69, Napoli, ITA, 80142
Arterra Bioscience SpA is a biotechnology company focused on the research and development of ingredients and natural solutions. It engages in the development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds; and production of high-tech raw materials with application in different industrial fields.
77GF Score

Get the complete analysis for MIL:ARBS

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.04
Price
€2.91
GF Value